{
    "nctId": "NCT00617539",
    "briefTitle": "Irinotecan and Temozolomide in Treating Patients With Breast Cancer Who Have Received Previous Treatment for Brain Metastases",
    "officialTitle": "A Phase II Study of Irinotecan and Temozolomide in Breast Cancer Patients With Brian Metastases That Have Progressed After Stereotactic Radiosurgery or Whole Brain Radiation",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Metastatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain\n\n  * Extracranial metastases allowed\n* Must have demonstrated progression of brain metastases after prior treatment for brain metastases, including any of the following:\n\n  * External beam radiotherapy\n  * Brachytherapy\n  * Stereotactic radiosurgery\n  * Surgery\n  * Chemotherapy\n  * Treatments with investigational drugs, biologics, or devices\n* Disease progression in the CNS must meet \u2265 1 of the following criteria:\n\n  * New lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI)\n  * Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI)\n* New or progressive lesions that do not meet measurable disease definition allowed\n* Leptomeningeal disease allowed if concurrent progression or parenchymal brain metastases\n* Not a candidate for surgical resection and/or further stereotactic radiosurgery\n* Hormone receptor status not specified\n\nPATIENT CHARACTERISTICS:\n\n* Menopausal status not specified\n* ECOG performance status 0-2\n* Life expectancy \u2265 1 month\n* Hemoglobin \u2265 10 g/dL (transfusion allowed)\n* ANC \u2265 1,500/mm\u00b3\n* Granulocyte count \u2265 1,500/mm\u00b3\n* Platelet count \u2265 100,000/mm\u00b3\n* Creatinine \u2264 1.5 mg/dL\n* Total bilirubin \u2264 1.5 times upper limit of normal (ULN)\n* AST and ALT \u2264 3 times ULN\n* Must be able to swallow and retain oral medications\n* No other active malignancy except for any of the following:\n\n  * Curatively treated basal or squamous cell carcinoma of the skin\n  * Carcinoma in situ of the cervix\n  * Other malignancies considered disease-free\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile patients must use effective contraception\n* No history of immediate or delayed-type hypersensitivity reaction to gadolinium contrast agents or other contraindication to gadolinium contrast\n* No other known contraindication to MRI including, but not limited to, any of the following:\n\n  * Cardiac pacemaker\n  * Implanted cardiac defibrillator\n  * Brain aneurysm clips\n  * Cochlear implant\n  * Ocular foreign body\n  * Shrapnel\n* No active or uncontrolled infection\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* Recovered from the side effects of prior chemotherapy, surgery, or radiotherapy for extracranial disease or brain metastases\n* Concurrent trastuzumab, bisphosphonate, and/or corticosteroid therapy allowed\n* At least 1 week since prior or on current stable dose of corticosteroid therapy\n* Patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication\n* Concurrent coumadin allowed\n* No prophylactic use of filgrastim (G-CSF) during first course of treatment",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}